Literature DB >> 12597258

Hawthorn.

Harry H S Fong1, Jerry L Bauman.   

Abstract

Crataegus monogyna Jacq (Lindm), C. laevigata (Poir) DC, or related Crataegus species, collectively known as hawthorn, have been used in the treatment of cardiovascular diseases. Clinical studies have found that standardized extracts show promise as adjunctive agents for the treatment of left ventricular dysfunction. Other trials consistently demonstrate its ability to improve exercise tolerance and symptoms of mild to moderate heart failure. Preliminary evidence indicates that it improves left ventricular performance, as measured by ejection fraction. In order to properly use hawthorn in the treatment of heart failure, a large, controlled, multicenter trial in which mortality serves as the primary endpoint is needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12597258     DOI: 10.1097/00005082-200207000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Nurs        ISSN: 0889-4655            Impact factor:   2.083


  5 in total

1.  Hawthorn (Crataegus monogyna Jacq.) extract exhibits atropine-sensitive activity in a cultured cardiomyocyte assay.

Authors:  Satin Salehi; Shannon R Long; Philip J Proteau; Theresa M Filtz
Journal:  J Nat Med       Date:  2008-08-12       Impact factor: 2.343

2.  Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease.

Authors:  Mary C Tassell; Rosari Kingston; Deirdre Gilroy; Mary Lehane; Ambrose Furey
Journal:  Pharmacogn Rev       Date:  2010-01

Review 3.  Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications.

Authors:  Seyed Fazel Nabavi; Solomon Habtemariam; Touqeer Ahmed; Antoni Sureda; Maria Daglia; Eduardo Sobarzo-Sánchez; Seyed Mohammad Nabavi
Journal:  Nutrients       Date:  2015-09-11       Impact factor: 5.717

Review 4.  Polyphenolic profile and biological activity of Chinese hawthorn (Crataegus pinnatifida BUNGE) fruits.

Authors:  Tunde Jurikova; Jiri Sochor; Otakar Rop; Jiri Mlcek; Stefan Balla; Ladislav Szekeres; Vojtech Adam; Rene Kizek
Journal:  Molecules       Date:  2012-12-06       Impact factor: 4.411

5.  Identification of Novel Melanin Synthesis Inhibitors From Crataegus pycnoloba Using an in Vivo Zebrafish Phenotypic Assay.

Authors:  Adamantia Agalou; Michael Thrapsianiotis; Apostolis Angelis; Athanasios Papakyriakou; Alexios-Leandros Skaltsounis; Nektarios Aligiannis; Dimitris Beis
Journal:  Front Pharmacol       Date:  2018-03-26       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.